Supplementary Tables
a The values are calculated based on Michaelis-Menten equation (Segel, 1975; Kim et al., 2004) . b The kinetic parameters for the mixture of competing LNAAs are calculated based on Eq.10.
c In this row, CL represent the mixture of L-tyrosine competing LNAAs (mixture of L-leucine, L-isoleucine, L-phenylalanine, L-tryptophan, L-valine, L-histidine and L-methionine).
d In this row, CL represent the kinetic parameters for the mixture of phenylalanine competing LNAAs (mixture of L-leucine, L-isoleucine, L-tyrosine, L-tryptophan, L-valine, L-histidine and Lmethionine). The volume of astrocyte is considered 742 µl (Ren et al., 1992; Anderova et al., 2011) (Table 1 ). f The concentration of LNAAs in the neuron and astrocyte compartments are based on measurements in the brain tissue (Shank and Campbell, 1984) . NA (not applicable) specifies that the large neutral amino acid was not reported to be a substrate for the transporter. For calculation of Vmax values, the total rat brain weight, volume and protein content and the volume of astrocyte and neuron are considered 1.81 g (Stewart, 1918) , 1737 µl, 105 mg protein/g brain (Banay-Schwartz et al., 1992) , 742 µl (Ren et al., 1992; Anderova et al., 2011) and 441.7 µl (Ren et al., 1992; Setou et al., 2004; Hosseini-Sharifabad and Nyengaard, 2007) (Table 1) , respectively. (Smith et al., 1987) 110.2 a (Kim et al., 2004) 1050 (Bröer et al., 2006) 0.075 (Smith et al., 1987; Tilgmann et al., 1992) 0.1128 (Shank and Campbell, 1984; Segawa et al., 1999) 0.0193 (Rao et al., 1995; Bröer et al., 2006) 77 (Currie et al., 1995) 0.73 (Currie et al., 1995) 52.1 (Kandera et al., 1968) L-valine 210 (Smith et al., 1987) 110.2 a (Kim et al., 2004) 190 (Yudkoff et al., 1996b; Bak et al., 2012) 0.089 (Smith et al., 1987; Tilgmann et al., 1992) 0.1427 (Shank and Campbell, 1984; Segawa et al., 1999) 0.0193 (Rao et al., 1995; Bröer et al., 2006) 211 (Currie et al., 1995) 1.22 (Currie et al., 1995) 86.5 (Kandera et al., 1968) L-leucine 29 (Smith et al., 1987) 224.2 (Kim et al., 2004) 81 (Bröer et al., 2006) 0.107 (Smith et al., 1987; Tilgmann et al., 1992) 0.184 (Shank and Campbell, 1984; Segawa et al., 1999) 0.0193 (Rao et al., 1995; Bröer et al., 2006) 149 (Currie et al., 1995) 1.35 (Currie et al., 1995) 66.7 (Kandera et al., 1968) L-isoleucine 56 (Smith et al., 1987) 139.2 a (Kim et al., 2004) 58 (Bröer et al., 2006) 0.109 (Smith et al., 1987; Tilgmann et al., 1992) 0.131 (Shank and Campbell, 1984; Segawa et al., 1999) 0.0154 (Rao et al., 1995; Bröer et al., 2006) 102 (Currie et al., 1995) 0.77 (Currie et al., 1995) 26.1 (Kandera et al., 1968) L-histidine 100 (Smith et al., 1987) 327 a (Kim et al., 2004) NA 0.111 (Smith et al., 1987; Tilgmann et al., 1992) 0.173 (Shank and Campbell, 1984; Segawa et al., 1999) NA 52 (Currie et al., 1995) 1.12 (Currie et al., 1995) 68.8 (Kandera et al., 1968) L-tyrosine 64 (Smith et al., 1987) 294 a (Kim et al., 2004) NA 0.175 (Smith et al., 1987; Tilgmann et al., 1992) 0.113 (Shank and Campbell, 1984; Segawa et al., 1999) NA 112 (Bongiovann i et al., 2003) 0.76 (Currie et al., 1995) 76.1 (Kandera et al., 1968) L-tryptophan 15 (Smith et al., 1987) 110.2 a (Kim et al., 2004) NA 0.099 (Smith et al., 1987; Tilgmann et al., 1992) 0.131 (Shank and Campbell, 1984; Segawa et al., 1999) NA 17 (Currie et al., 1995) 0.15 (Currie et al., 1995) 13.5 (Amorini et al., 2017) L-methionine 40 (Smith et al., 1987) 430.7 a (Kim et al., 2004) 40 (Bröer et al., 2006) 0.046 (Smith et al., 1987; Tilgmann et al., 1992) 0.156 (Shank and Campbell, 1984; Segawa et al., 1999) 0.0193 (Rao et al., 1995; Bröer et al., 2006) 96 (Currie et al., 1995) 0.37 (Currie et al., 1995) 38.6 (Kandera et al., 1968 The standard deviations associated with the calculated baseline concentrations are estimated based on the sensitivity studies (Sensitivity analysis section). a In this column, TL and CL represent tyrosine and tyrosine competing LNAAs, respectively. For the calculations of baseline concentrations, the plasma concentration of TL and CL are considered as constant input, fixed at 112 (Bongiovanni et al., 2003) and 704 (Currie et al., 1995) µM, respectively (Suppl. Table 1) .
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b In this column, TL and CL represent phenylalanine and phenylalanine-competing LNAAs, respectively. For the calculations of baseline concentrations, the plasma concentration of TL and CL are defined as constant input, fixed at 77 (Currie et al., 1995) and 739 (Currie et al., 1995; Bongiovanni et al., 2003) µM, respectively (Suppl. Table 1 ).
C
The baseline initialization for TL and CL are based on values reported in Suppl. Table 1. d The microvascular brain endothelial cells are initialized randomly as the values were not available. The specified range is based on the total concentration in the brain tissue e The micro dialysis samples are collected from rat lateral hypothalamus. The initialization for the neuron and astrocyte compartments are based on the measured baseline concentrations of LNAAs in brain tissue (Suppl. Table 1 ) (Shank and Campbell, 1984) .
Evaluation of brain ISF post-stimuli responses under the assumption of LAT1 as the dominant LNAA transporter in astrocytes
As mentioned in the Introduction section, several studies have shown that LAT2 is the dominant LNAA transporter in primary astrocyte cells (Yudkoff et al., 1996a; Kim et al., 2004; Braun et al., 2011) . However, Zhang Y, et al. (Zhang et al., 2014) showed that freshly isolated astrocytes specifically express higher levels of LAT1 mRNA compared LAT2 mRNA (Zhang et al., 2014) .
Even though the mRNA expression does not necessarily correspond to protein abundance and dominance (Taslimifar et al., 2017) , and although there is no report on the astrocytic transport activity of LAT1 in non-cultured cell assays, we have additionally checked whether considering LAT1 instead of LAT2 as dominant astrocytic AAT would modify our conclusion on the functional polarity of MBECs with either asymmetric bi-directional kinetics and/or asymmetric distribution of (Kandera et al., 1968) 16.6±1.1 274.0 ± 20.9 [0-76.1] (Kandera et al., 1968) [TL] b MBEC µM 1022.4 ±130.7 1408.8 ± 235.7 [0-376.2] (Kandera et al., 1968; Amorini et al., 2017) 104.5±6.6 1722.2 ± 131.5 [0-352.2] (Kandera et al., 1968; Amorini et al., 2017) [CL] b
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MBEC
Brain interstitial fluid e µM 0.4 ± 0.03 0.4 ± 0.03 0.7 (Currie et al., 1995) 1.2±0.1 1.0±0.1 0.8 (Currie et al., 1995) [TL] b ISF µM 3.8 ± 0.3 3.8 ± 0.3 5.7 (Currie et al., 1995) 7.3±0.9 6.5±0.9 5.7 (Currie et al., 1995) [CL] b ISF Astrocyte f µM 40.2 ± 4.6 40.6 ± 4.8 52.1 (Kandera et al., 1968) 66.1±6.7 61.5 ± 7.0 76.1 (Kandera et al., 1968) [TL] b Ast µM 385.7 ± 44 389.7 ± 46.0 376.2 (Kandera et al., 1968; Amorini et al., 2017) 415.5±41.8 386.5± 43.7 352.2 (Kandera et al., 1968) [CL] b Ast Neuron f µM 54.3 ± 6.0 53.4 ± 7.0 52.1 (Kandera et al., 1968) 77.1±9.3 75.1 ± 9.0 76.1 (Kandera et al., 1968) [TL] b Neu µM 375.2 ± 39.8 368.7 ± 46.9 376.2 (Kandera et al., 1968; Amorini et al., 2017) 354.8±41.3 316.6 ± 41.4 352.2 (Kandera et al., 1968; Amorini et al., 2017) [CL] b
Neu
The bi-directional and expression constant of MBEC LAT1
LAT1 in MBECs. To this end, we assumed LAT1 to be the dominant astrocytic LNAA transporter, replacing LAT2 in the astrocyte. In this situation, given that the intra-compartmental fluxes depend on the choice of the dominant transporters, we simply substituted the parameters of Eq. (7) (Methods section) with those of LAT1 for astrocytes (reported in Suppl. Table 3 ) and similarly calculated the baseline (pre-stimulus) state of the NVU system as reported in Suppl. Table 3 . We then calculated the post-stimulus response of LNAA concentrations (Suppl. Fig.1 ) upon perturbation of plasma Ltyrosine and L-phenylalanine concentrations ( Figs. 2A and 2C) . All model parameters except for kinetic parameters specific to LAT1 in the astrocyte (Suppl . Table 3 ) remain the same as in the nominal model (Table 1 ). The bi-directional kinetic constant for astrocyte LAT1 is considered equal to the corresponding value in the MBEC LAT1 ( RK LAT1 ). The time evolution of the plasma concentration of L-tyrosine and L-phenylalanine and of competing LNAAs is plotted as percentage of the baseline values in Suppl. Fig. 1 . The error bars given for the baseline concentrations were calculated based on sensitivity studies as described in the Sensitivity analysis section. We compared the model predictions for the ISF response to IP L-tyrosine and L-phenylalanine injection with results of in vivo measurements (Bongiovanni et al., 2003; Bongiovanni et al., 2010) , in the range from 1 (symmetric case) and 1300 (highly asymmetric bi-directional kinetics (Meier et al., 2002) ) (Suppl. Fig. 1A,C) . We found a close agreement between our model calculations and experimental measurements assuming asymmetric MBEC LAT1 kinetics (best with RK LAT1 = 220 and 45, respectively, for L-tyrosine and L-phenylalanine IP injection cases), while the model failed to reproduce the experimental data when the bi-directional kinetics of LAT1 were assumed to be symmetric in MBECs (Suppl. Fig. 1A, C) .
To evaluate the hypothesis of asymmetric distribution of LAT1 at the BBB, we varied the abluminal to luminal expression ratio of LAT1, RE LAT1 , between 0.01 to 10 (representing highly asymmetric abluminal to luminal expression ratio) while we assumed the bi-directional kinetics of LAT1 to be symmetric ( RK LAT1 = 1). The numerical results obtained with asymmetric transporter expression agreed well with in vivo experimental data, best for an expression kinetic constant of RE LAT1 =0.12.
Taken together, our results show that assuming LAT1 rather than LAT2 as the dominant astrocytic AAT does not affect our conclusion on functional polarity of MBECs with either strong asymmetric kinetics of LAT1 and/or its expression at the BBB. Further exploration of the correlation between astrocyte mRNA is required to characterize the function of LAT1 in astrocytes in vivo. µM 11 (Smith et al., 1987) 64 (Smith et al., 1987) K m,abs,LAT1,TL ISF(Ast) µmol/min 0.184 (Shank and Campbell, 1984) 0.132 (Shank and Campbell, 1984) V max,LAT1,TL µM 52.9 (Smith et al., 1987) 37 (Smith et al., 1987) K m,abs,LAT1,CL ISF(Ast) µmol/min 0.178 c (Shank and Campbell, 1984) 0.184 c (Shank and Campbell, 1984) V max,LAT1,CL Table 4 ).
